BR0211836A - Carbonic anhydrase inhibitor - Google Patents

Carbonic anhydrase inhibitor

Info

Publication number
BR0211836A
BR0211836A BR0211836-0A BR0211836A BR0211836A BR 0211836 A BR0211836 A BR 0211836A BR 0211836 A BR0211836 A BR 0211836A BR 0211836 A BR0211836 A BR 0211836A
Authority
BR
Brazil
Prior art keywords
carbonic anhydrase
drugs
diseases
treating
anhydrase inhibitor
Prior art date
Application number
BR0211836-0A
Other languages
Portuguese (pt)
Inventor
Janet M O'neal
Jaime L Masferrer
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0211836A publication Critical patent/BR0211836A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

"INIBIDOR DE ANIDRASE CARBÈNICA". Método de tratar ou prevenir distúrbios associados à anidrase carbónica ou doenças em um indivíduo em necessidade de tal tratamento como prevenção compreendendo administração de inibidores de ciclooxigenase-2, ou compostos estruturalmente relacionados, tendo propriedades inibitórias de anidrase carbónica, bem como combinações dos inibidores de ciclooxigenase-2, ou compostos estruturalmente relacionados, com drogas ou agentes antiinflamatórios, drogas ou agentes antineoplásicos ou drogas ou agentes oftálmicos em métodos de tratamento e prevenção dos distúrbios ou doenças."CARBONIC ANIDRASE INHIBITOR". A method of treating or preventing carbonic anhydrase disorders or diseases in an individual in need of such treatment as prevention comprising administering cyclooxygenase-2 inhibitors, or structurally related compounds having carbonic anhydrase inhibitory properties, as well as combinations of cyclooxygenase inhibitors -2, or structurally related compounds, with drugs or anti-inflammatory agents, drugs or antineoplastic agents or drugs or ophthalmic agents in methods of treating and preventing disorders or diseases.

BR0211836-0A 2001-08-10 2002-08-09 Carbonic anhydrase inhibitor BR0211836A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31156101P 2001-08-10 2001-08-10
PCT/US2002/025447 WO2003013655A2 (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitors

Publications (1)

Publication Number Publication Date
BR0211836A true BR0211836A (en) 2004-12-14

Family

ID=23207450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211836-0A BR0211836A (en) 2001-08-10 2002-08-09 Carbonic anhydrase inhibitor

Country Status (7)

Country Link
EP (1) EP1414522A2 (en)
JP (1) JP2005501083A (en)
AU (1) AU2002331050A1 (en)
BR (1) BR0211836A (en)
CA (1) CA2456939A1 (en)
MX (1) MXPA04001268A (en)
WO (1) WO2003013655A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
EA010904B1 (en) * 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
LT5504B (en) * 2006-08-02 2008-06-25 Biotechnologijos Institutas Benzimidazo[1,2-c][1,2,3]thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof
CA2777071A1 (en) * 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
CN107922345B (en) * 2015-07-01 2021-03-23 圣诺康生命科学公司 Arylsulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432193T2 (en) * 1993-11-30 2004-01-15 Searle & Co Substituted pyrazolyl-benzenesulfonamides and their use as cyclooxygenase II inhibitors
JP3181190B2 (en) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 Oxazole derivatives
US5944021A (en) * 1995-06-07 1999-08-31 Rodriguez; Victorio C. Therapeutic use of a carbonic anhydrase enzyme inhibitor for the treatment of brain edema
ATE408607T1 (en) * 1996-04-12 2008-10-15 Searle Llc SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRECURSORS OF COX-2 INHIBITORS
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors

Also Published As

Publication number Publication date
MXPA04001268A (en) 2004-05-27
AU2002331050A1 (en) 2003-02-24
EP1414522A2 (en) 2004-05-06
WO2003013655A2 (en) 2003-02-20
JP2005501083A (en) 2005-01-13
CA2456939A1 (en) 2003-02-20
WO2003013655A3 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
NO20034549D0 (en) Treatment of type 2 diabetes with dipeptidyl peptidase IV inhibitors
BR9911666A (en) Pharmaceutical combination, use of the combination, process for treating an inflammatory disease in a person suffering from or susceptible to such disease, and pharmaceutical composition
NO20050807L (en) Pharmaceutical compositions including dextromethorphan and quinidine for the treatment of neurological disorders
WO2005009342A3 (en) Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
BR0212141A (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammation and other diseases
BR0308243A (en) Compound, pharmaceutical formulation, and, methods of treating diabetes, alzheimer's disease, and inhibiting gsk-3 in a mammal
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
ATE472325T1 (en) INTRACORPORAL MEDICATIONS FOR THE PHOTODYNAMIC TREATMENT OF DISEASES
BR0307050A (en) Compound, pharmaceutical composition, methods for treating prostaglandin d2 mediated diseases, for treating nasal congestion, for treating allergic asthma, and for treating allergic rhinitis, pharmaceutically acceptable salt, and use of a compound or salt
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
BR0314797A (en) Pyrimidineamide derivatives and their use
SE9704644D0 (en) New use
WO2004043352A8 (en) Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
CY1106155T1 (en) USE OF 3-BENZOPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF AMPHIBLISTROID DISORDERS
WO2004100878A3 (en) Method of treatment of hemorrhagic disease using a factor viia/tissue factor inhibitor
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
BR0211836A (en) Carbonic anhydrase inhibitor
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
BR0317539A (en) Methods and compositions for treating herpes virus infections using selective cyclooxygenase-2 inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
BR0307022A (en) Method of treating a patient who needs analgesia
MXPA05014143A (en) Coumarin derivatives for the treatment of ophthalmic disorders.
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
RS50681B (en) A combination of a taxane and cyclin-dependent kinase inhibitor
BR0017367A (en) Use of melagatran or a pharmaceutically acceptable derivative thereof, method of treating an ischemic disorder in a patient having, or at risk for, nonvalvular atrial fibrillation and pharmaceutical formulation
AR020740A1 (en) COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/635 (2006.01), A61P 3/12 (2006.01), A61P 7